Obtaining an accepted Investigational New Drug application to operate an umbilical cord blood bank
Authors:
- 1 April 1999
- journal article
- Published by Wiley in Transfusion
- Vol. 39 (4) , 357-363
Abstract
The residual blood left in the placenta, previously considered a biologic waste, contains sufficient hematopoietic stem and progenitor cells to consistently engraft at least a small recipient. Over the past several years, more than 500 HLA-matched, related and unrelated, allogeneic cord blood transplants have been performed. Consequently, public and private cord blood banks are being developed to meet future demands. Thus, the definition of a suitable and effective cord blood component needs to be critically defined. In February 1997, the US Food and Drug Administration (FDA) proposed that cord blood banks should operate under an Investigational New Drug (IND) license. Standard operating procedures were designed using standards from the Foundation for Accreditation of Hematopoietic and Cellular Therapy, the American Association of Blood Banks, and the National Marrow Donor Program and in accordance with current good manufacturing practices. The standard operating procedures were field-tested and submitted to the FDA. Issues of the utmost concern to the FDA dealt with transplant recipient outcome data collection, donor recruitment, sample tracking, the use of unlicensed materials, and the reporting of positive infectious disease results. After three attempts, an IND application was approved. To obtain approval of an IND application, cord blood banks need a set of standard operating procedures that describe cord blood collection, processing, freezing, and storage. Issues relating to potential cord blood recipient identification, cord blood shipping, and reporting of transplant recipient outcomes are also needed. The IND process provides an opportunity for outside reviewers to make suggestions that may be included in the standard operating procedures.Keywords
This publication has 9 references indexed in Scilit:
- Guidelines for the collection, processing, storage and of administration of hemopoietic stem and progenitor cells for transplantation. Report of the Working Party on Hemopoietic Stem Cell Processing, Hematology Discipline Advisory Committee, The Royal College of Pathologists of AustralasiaPathology, 1998
- Placental and/or Umbilical Cord Blood: An Alternative Source of Hematopoietic Stem Cells for TransplantationBlood, 1997
- Outcome of Cord-Blood Transplantation from Related and Unrelated DonorsNew England Journal of Medicine, 1997
- Index 1997Médecine & Droit, 1997
- Placental Blood as a Source of Hematopoietic Stem Cells for Transplantation into Unrelated RecipientsNew England Journal of Medicine, 1996
- Processing and cryopreservation of placental/umbilical cord blood for unrelated bone marrow reconstitution.Proceedings of the National Academy of Sciences, 1995
- Allogeneic sibling umbilical-cord-blood transplantation in children with malignant and non-malignant diseaseThe Lancet, 1995
- Hematopoietic Reconstitution in a Patient with Fanconi's Anemia by Means of Umbilical-Cord Blood from an HLA-Identical SiblingNew England Journal of Medicine, 1989
- Human umbilical cord blood as a potential source of transplantable hematopoietic stem/progenitor cells.Proceedings of the National Academy of Sciences, 1989